What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class”In the company’s words, NCT06547840 on ClinicalTrials.gov
- Tested for
- Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer, Endometrial Cancer, Advanced Endometrial Cancer
- Main trialPhase 1
- “EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18…”In the company’s words, NCT06547840 on ClinicalTrials.gov
Other drugs for Advanced Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jul 2026 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026